[Reporter's View] Restricting vs expanding access
By Eo, Yun-Ho | translator Alice Kang
24.12.05 05:40:00
가나다라
0
![](http://pds.dreamdrug.com/newseng_images/202412/6511_1.png)
The addition of a post-listing control system seems to be a fixed deal. The establishment of the Drug Performance Evaluation Office under the Health Insurance Review and Assessment Policy Research Institute has already taken place, and government officials have been publicly discussing using RWD (Real-world data) for drugs subject to the exemption from submission of pharmacoeconomic evaluation data.
So the key to its implementation will be in the contents of the ‘dialogue.’ Will the system act as another mechanism to lower drug prices and cause much friction, or will it be a reasonable 'uncertainty resolution' device per government claims?
Is the PE exemption system necessary? Its need
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)